Description: This session will review reinsurance fundamentals, risk assessment techniques, optimization strategies, and regulatory considerations through case studies and best practices. Attendees will gain insights into enhancing capital management, risk mitigation, and improving operating results, utilizing practical insights from both reinsurers and direct experience.

Description: Join us for this popular annual webcast covering the latest considerations for the year's U.S. statutory financial reporting work. Get ready to hear from three expert speakers, who will discuss cash flow testing and this year’s New York and California holiday letters, the impact of recent interest rate changes including treatment of negative IMR, potential changes to statutory financial reporting due to climate change, and updates regarding Principle Based Reserves.

Description: This will be an engaging and interactive session that will begin with a game show to level set basic knowledge of LDTI. Next, you will have an opportunity to ask the experts in-depth questions about anything related to LDTI. Finally, we will invite the 2023 adopters to share their experiences with the 2025 adopters. The exact content will be driven by participants but is expected to include MRB valuation approaches, LFPB reinsurance topics, DPL, DAC, and disclosure topics. At the end of the session, participants will understand different perspectives from industry experts and peers on the many facets of LDTI.

Description: Human longevity is one of the great success stories of the past century, and there is growing consensus that there are further gains to come. What will these future gains look like, where will they come from and how likely are they to happen. Furthermore, how do we as actuaries deal with the uncertainty when trying to predict future long-term mortality improvements more than 20 years into the future. This is one of the most important assumptions on the balance sheet that insurers and reinsurers make, so it is important to have a strong perspective on it. Our presentation will give attendees a view into some of the core components of how to assess long-term mortality improvements by looking at the cyclical nature across different countries of life expectancy. It will also deep dive into the different drivers of life expectancy over the past cycle driven largely by improved diagnosis and treatment of cardiovascular disease (CVD) and cessation of smoking, which ended in about 2010. It will then discuss how population mortality improvement has slowed and plateaued in many major countries.

Description: Statutory and GAAP metrics are useful for external audiences such as regulators and investors since they provide a consistent framework for viewing and comparing multiple companies at a point in time. However, their uses are more limited for managers who require more real-time information in making strategic decisions. Many insurers are developing internal metrics such as Value of New Business (VNB) for better profitability insights at the point of sale, to understand how new business profitability changes over time and to allow for quicker decision making. By leveraging existing models and reporting processes, insurers can reduce the additional effort involved in applying VNB toward applications such as pricing, capital allocation and risk management. Find out more about key considerations for developing and using VNB.

Description: Mortality Improvement is fundamental to setting your mortality assumptions. Creating your own Mortality Improvement assumption may seem like a Herculean task. The truth is creating a mortality improvement assumption with tools provided by the SOA, or the Continuous Mortality Investigation (CMI) make the process easy. Leaving you with the Herculean task of deciding if the assumption you created fits your product. Expect to learn about the CMI tool and the SOA's Mortality Improvement Model (MIM) tool, how you might get data to use in those tools, and what assumptions you need to make outside of data like what will the MI be in 20 or 30 years? Whether it is the general population, a segment of the general population, or certain causes of death, you will get very different answers.

Description: Modifiable risk factors stand out today as significant contributors to diseases, and yet we as an industry haven't tackled this. Instead, we sit by almost passively as obesity, diabetes and hypertension rates continue to skyrocket. In fact, obesity and overweight is now over 70% of the US population and has turned into the forgotten pandemic. Globally, no country in the world has improved their obesity percentage rates during the past 15 years. Insurers are starting to explore health interventions which have the potential to reduce claims and change people's behavior.

Description: There are a variety of regulatory changes that are being contemplated by the National Association of Insurance Commissioners (NAIC) that have the potential to materially impact actuarial, statutory reporting and disclosure requirements relating to reinsurance. This session will provide an introduction to these changes, explaining both the motivation as well as the potential impact these proposed changes may have on US ceding companies. The focus of the presentation will be primarily on changes affecting Asset Adequacy Testing and statutory risk transfer for combination Coinsurance / Yearly Renewable Term agreements. An update will be provided regarding industry responses to proposed changes and the potential timing for implementation of these new requirements.

Description: The session will start by looking at emerging trends in US population mortality improvement focusing especially on recent deviations from the traditional norms influenced by factors such as the prescription drug epidemic, aging populations, improvements in medical technology and socioeconomic differentiation. Explore the recently developed SOA Research Institute tool looking at US life insured mortality experience to see to what extent insights from the population view are present in insured mortality and how to make the best use of the tool. The session will conclude with observations on key points to keep in mind in your own understanding of mortality improvement development as well as engage the audience to gather your perspective.

Description: Many companies are facing challenges with their inforce UL business. These “distressed” or non-core blocks of business can be a drag on earnings, return on capital, and/or internal resources. With the pressures of today's marketplace, companies are seeking efficient strategies for managing these blocks. The good news is that strategies exist such that inforce UL business can be optimized with some attention. Learn about some options and levers companies have available to help manage these blocks.